Compare Aurora Cannabis Inc (ACB) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance

Aurora Cannabis (ACB) trades at $2.99, up 0.34% with a bullish technical signal despite mixed earnings. The company achieved record annual medical cannabis revenue growth of 18% YoY to $288.6 million in FY2026, but faces margin pressure from Canadian reimbursement changes. Recent Q1 2027 earnings beat expectations with $0.04 EPS versus -$0.13 estimate, though revenue declined to $67.6 million. The stock shows strong institutional support with shareholder approval of board measures and EU-GMP certification for international expansion.

ACB presents a high-risk opportunity with significant volatility. While international medical cannabis growth and operational improvements provide upside potential, persistent net losses, negative ROE/ROA, and Canadian market challenges create substantial headwinds. Analyst consensus remains cautious with only 21% buy ratings, reflecting concerns about profitability timeline and competitive pressures in the evolving cannabis sector.

PALL trades at $25.05, up 0.64% with bullish technical signals from moving averages. The stock recently underwent a 1:5 split on May 18, 2026. Technical indicators show mixed signals with RSI suggesting mild overbought conditions while ADX indicates strong trend strength. Support and resistance levels cluster around $25-$26, creating a key price zone.

PALL presents a contrarian opportunity as palladium prices remain 47% below January 2026 highs. Supply risks and industrial demand support long-term fundamentals, though the ETF faces commodity price volatility and Federal Reserve policy uncertainty as near-term headwinds.